Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128162 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL30158792 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL26347047 | 0.89 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL11367332 | 0.87 | PPM1B (0.38) | PPM1BPTPN1PPP1CCALDH1A1NPSR1 | |
| SCHEMBL8274706 | 0.84 | TSHR (0.40) | ALDH1A1MAPT | |
| SCHEMBL400097 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL208304 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL13242445 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL17451842 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL29132902 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778898-A1 | NOVEL HYDROLASE AND METHOD FOR PRODUCING (1S,2S)-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE CARBOXYLIC ACID USING SAME | API Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2813500-B1 | Intermediates for the preparation of hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2225249-B1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| EP-2813500-A1 | Intermediates for the preparation of hepatitis C virus inhibitors | Bristol-Myers Squibb Company (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-1684745-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2086994-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2008064057-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008019289-A2 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007056120-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007044933-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | HCCS, HAVCR2, EIF2AK2 | CA1 4728/4885CA2 4789/4885CA12 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.